| |
Median OS, months
|
HR (95% CI)
|
P-value
|
Median PFS, months
|
HR (95% CI)
|
P-value
|
|---|
|
Age
| | | | | | |
|
< 60 years
|
7.0
|
0.79 (0.39-1.61)
|
0.512
|
2.9
|
0.50 (0.24-1.01)
|
0.059
|
|
≥ 60 years
|
9.2
| | |
9.6
| | |
|
Gender
| | | | | | |
|
Male
|
10.1
|
1.33 (0.64-2.76)
|
0.444
|
8.1
|
1.07 (0.29-2.29)
|
0.862
|
|
Female
|
5.2
| | |
3.5
| | |
|
Performance status
| | | | | | |
|
0-1
|
10.1
|
1.72 (0.79-3.73)
|
0.168
|
8.1
|
1.15 (0.51-2.59)
|
0.728
|
|
2-4
|
4.8
| | |
3.6
| | |
|
B symptom
| | | | | | |
|
Absent
|
9.2
|
1.29 (0.62-2.66)
|
0.490
|
8.1
|
1.09 (0.51-2.33)
|
0.810
|
|
Present
|
7.0
| | |
3.6
| | |
|
Stage
| | | | | | |
|
1-2
|
4.0
|
0.21(0.02-0.72)
|
0.147
|
3.6
|
0.45 (0.05-3.44)
|
0.445
|
|
3-4
|
9.2
| | |
8.1
| | |
|
Extranodal involvement
| | | | | | |
|
0-1
|
10.1
|
1.13 (0.56-2.28)
|
0.729
|
14.7
|
1.27 (0.61-2.67)
|
0.518
|
|
≥ 2
|
8.1
| | |
3.9
| | |
|
Bone marrow involvement
| | | | | | |
|
Negative
|
11.9
|
1.33 (0.66-2.67)
|
0.414
|
9.5
|
1.29 (0.64-2.61)
|
0.467
|
|
Positive
|
7.3
| | |
7.0
| | |
|
LDH
| | | | | | |
|
Normal
|
9.2
|
1.51 (0.45-4.97)
|
0.498
|
8.1
|
1.54 (0.46-5.10)
|
0.474
|
|
Elevated
|
7.6
| | |
7.3
| | |
|
PIT
| | | | | | |
|
Group 1-2
|
16.9
|
1.35 (0.58-3.14)
|
0.476
|
8.1
|
1.06 (0.45-2.48)
|
0.883
|
|
Group 3-4
|
7.6
| | |
7.3
| | |
|
ALC
| | | | | | |
|
≥ 1.0 × 109/l
|
10.6
|
3.09 (1.52-6.32)
|
0.002
|
11.9
|
4.02 (1.80-8.97)
|
0.001
|
|
< 1.0 × 109/l
|
4.0
| | |
2.9
| | |
- LDH, lactate dehydrogenase; IPI, International Prognostic Index; L, low; LI, low-intermediate; HI, high-intermediate; H, high; PIT, Prognostic Index for peripheral T-cell lymphoma; ALC, absolute lymphocyte count; OS, overall survival; PFS, progression free survival.
